Skip to Main Content

Paper Details

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.
Clin Cancer Res
227
2017
A vs, Anastrozole, C1D1, CDK4/6, Cyclin-Dependent Kinase 4/6, Cyclin-dependent kinase (CDK) 4/6, E2F-target gene, ER, ER+/HER2- breast cancer, Estrogen, Estrogen Receptor, Estrogen Receptor-Positive Breast Cancer, HER2, Ki67, PIK3CA, Palbociclib, anastrozole, breast cancer, early-stage, estrogen, estrogen receptor, estrogen receptor-positive (ER+) breast cancer, luminal subtype, palbociclib, patients, primary breast cancer
Author NameAffiliation
Cynthia X MaWashington University School of Medicine
Matthew P GoetzMayo Clinic
Jeremy HoogWashington University School of Medicine
Foluso O AdemuyiwaWashington University School of Medicine
Zhanfang GuoWashington University School of Medicine
Nicholas C SpiesMcDonnell Genome Institute, Washington University School of Medicine
Zachary L SkidmoreMcDonnell Genome Institute, Washington University School of Medicine
Obi L GriffithWashington University School of Medicine
Obi L GriffithMcDonnell Genome Institute, Washington University School of Medicine
Obi L GriffithWashington University School of Medicine
Malachi GriffithMcDonnell Genome Institute, Washington University School of Medicine
Malachi GriffithWashington University School of Medicine
Souzan SanatiWashington University School of Medicine
Matthew J EllisBaylor College of Medicine
  • 1 - 14

Datasets

Release 1.2